Cortexyme Inc. (NASDAQ:CRTX) Socks Falls After Providing New GAIN Trial Data

April 18, 2022

Cortexyme Inc. (NASDAQ:CRTX) dropped 18% last week. The clinical-stage biopharmaceutical firm that is pioneering upstream therapy approaches to enhance the lives of individuals with degenerative diseases has presented the latest biomarker and engagement dated from the GAIN Trial. Trading Data On Thursday, CRTX stock fell 3.32% to $4.66 with more than 381K shares traded, compared to volume of 776k shares. The stock moved within a range of $4.4600 – 4.8500…

Read More >>